Mammoth Biosciences IPO

mammoth.bio

Mammoth Biosciences is a biotechnology company that, through the discovery and development of novel CRISPR systems, is enabling the full potential of its platform to improve lives by reading and writing the code of life. The company was founded by Trevor Martin Ph.D., Janice Chen Ph.D., Lucas Harrington, and Jennifer Doudna Ph.D. in 2017 and is headquartered in Brisbane, CA.

Founded2017
Total Funding to Date$257.38MM
Register for Details

For more details on financing and valuation for Mammoth Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Mammoth Biosciences Ticker Symbol

Mammoth Biosciences does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

Mammoth Biosciences Stock Price

The stock price for Mammoth Biosciences will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Major Investors for Mammoth Biosciences

Mayfield Fund
Foresite Capital
Decheng Capital
NFX
Redmile Group

Mammoth Biosciences Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
9/9/2021 Series D and D-1 $150MM raised $XXX.XX $XXX.XX
11/4/2020 Series C and C-1 $45.11MM raised $XXX.XX $XXX.XX
1/30/2020 Series B and B-1 $44.18MM raised $XXX.XX $XXX.XX
8/8/2018 Series A $18.1MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Other companies like Mammoth Biosciences in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$334.19MM
Sector